Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry-Reference-Cited by-同舟云学术

Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry

Published:2020-03-10 Issue:3 Volume:36 Page:408-416
ISSN:1880-4276
Container-title:Journal of Arrhythmia
language:en
Short-container-title:J Arrhythmia

Author:

Ma Changsheng¹^ORCID,Riou França Lionel²,Lu Shihai³,Diener Hans‐Christoph⁴,Dubner Sergio J.⁵,Halperin Jonathan L.⁶,Li Qiang⁷,Paquette Miney⁸,Teutsch Christine²,Huisman Menno V.⁹,Lip Gregory Y. H.¹⁰¹¹^ORCID,Rothman Kenneth J.¹²,

Affiliation:

1. Cardiology Department Atrial Fibrillation Center Beijing Anzhen Hospital Capital Medical University Beijing China

2. Sanofi‐Aventis Recherche et Développement Chilly‐Mazarin France

3. Biostatistics and Data Sciences Department Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield CT USA

4. Department of Neurology University of Duisburg‐Essen Essen Germany

5. Clínica y Maternidad Suizo Argentina Buenos Aires Argentina

6. Icahn School of Medicine at Mount Sinai New York NY USA

7. Boehringer Ingelheim (China) Investment Co. Ltd. Beijing China

8. Department of Medicine Boehringer Ingelheim Burlington ON Canada

9. Department of Thrombosis and Hemostasis Leiden University Medical Center Leiden the Netherlands

10. Liverpool Centre for Cardiovascular Science University of Liverpool and Liverpool Heart & Chest Hospital Liverpool UK

11. Aalborg Thrombosis Research Unit Department of Clinical Medicine Aalborg University Aalborg Denmark

12. RTI Health Solutions Research Triangle Institute Research Triangle Park NC USA

Funder

Boehringer Ingelheim International GmbH

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/joa3.12321

Reference28 articles.

1. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

2. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

3. Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation

4. Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry

5. One-year Clinical Prediction in Chinese Ischemic Stroke Patients Using the CHADS2 and CHA2DS2-VASc Scores: The China National Stroke Registry

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Knowledge, Attitude and Practice Toward Intracerebral Hemorrhage Prevention Among Patients Taking Oral Anticoagulants;International Journal of General Medicine;2024-07

2. Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registry;Scientific Reports;2024-02-02

3. Safety of dabigatran;Glavvrač (Chief Medical Officer);2024-01-22

4. Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registry;Thrombosis Journal;2023-08-01

5. An analysis of antithrombotic therapy in elderly patients with atrial fibrillation undergoing percutaneous coronary interventions;Clinical and Experimental Pharmacology and Physiology;2023-04-27